Skip to main content
PMC home page
NPJ Breast Cancer logoLink to NPJ Breast Cancer
. 2021 Feb 12;7:16. doi: 10.1038/s41523-021-00224-w

Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants

Matteo Lambertini 1,2,✉, Marcello Ceppi 3, Anne-Sophie Hamy 4, Olivier Caron 5, Philip D Poorvu 6, Estela Carrasco 7, Albert Grinshpun 8, Kevin Punie 9, Christine Rousset-Jablonski 10, Alberta Ferrari 11, Shani Paluch-Shimon 12, Angela Toss 13, Claire Senechal 14, Fabio Puglisi 15,16, Katarzyna Pogoda 17, Jose Alejandro Pérez-Fidalgo 18, Laura De Marchis 19, Riccardo Ponzone 20, Luca Livraghi 21,22, Maria Del Pilar Estevez-Diz 23, Cynthia Villarreal-Garza 24,25, Maria Vittoria Dieci 26,27, Florian Clatot 28, Francois P Duhoux 29, Rossella Graffeo 30, Luis Teixeira 31, Octavi Córdoba 32, Amir Sonnenblick 33, Arlindo R Ferreira 34, Ann H Partridge 6, Antonio Di Meglio 35, Claire Saule 36, Fedro A Peccatori 37, Marco Bruzzone 3, Marie Daphne t’Kint de Roodenbeke 38, Lieveke Ameye 39, Judith Balmaña 7, Lucia Del Mastro 1,40,#, Hatem A Azim Jr 25,#
PMCID: PMC7880991  PMID: 33579978

Abstract

Young breast cancer (BC) patients carrying a germline BRCA pathogenic variant (mBRCA) have similar outcomes as non-carriers. However, the impact of the type of gene (BRCA1 vs. BRCA2) and hormone receptor status (positive [HR+] vs. negative [HR−]) on clinical behavior and outcomes of mBRCA BC remains largely unknown. This is an international, multicenter, hospital-based, retrospective cohort study that included mBRCA patients diagnosed, between January 2000 and December 2012, with stage I–III invasive early BC at age ≤40 years. From 30 centers worldwide, 1236 young mBRCA BC patients were included. Among 808 and 428 patients with mBRCA1 or mBRCA2, 191 (23.6%) and 356 (83.2%) had HR+tumors, respectively (P < 0.001). Median follow-up was 7.9 years. Second primary BC (P = 0.009) and non-BC malignancies (P = 0.02) were more frequent among mBRCA1 patients while distant recurrences were less frequent (P = 0.02). Irrespective of hormone receptor status, mBRCA1 patients had worse disease-free survival (DFS; adjusted HR = 0.76, 95% CI = 0.60–0.96), with no difference in distant recurrence-free interval (DRFI) and overall survival (OS). Patients with HR+ disease had more frequent distant recurrences (P < 0.001) and less frequent second primary malignancies (BC: P = 0.005; non-BC: P = 0.18). No differences in DFS and OS were observed according to hormone receptor status, with a tendency for worse DRFI (adjusted HR = 1.39, 95% CI = 0.94–2.05) in patients with HR+ BC. Type of mBRCA gene and hormone receptor status strongly impact BC clinical behavior and outcomes in mBRCA young patients. These results provide important information for patients’ counseling on treatment, prevention, and surveillance strategies.

Subject terms: Breast cancer, Cancer genetics

Introduction

In women aged ≤40 years, breast cancer is the most common malignancy and the first cause of cancer-related mortality1. Despite the higher risk of developing triple-negative and HER2-positive breast cancer, the majority of breast malignancies arising in young patients are hormone receptor-positive tumors2. In young patients, the prognosis for hormone receptor-positive breast cancers is worse when compared to their older counterparts3.

Other age-related issues should be considered in the management of breast cancer in young women4. Among them, genetic counseling and testing is key. Approximately 12% of cases arising in women aged ≤40 years are related to germline pathogenic variants in BRCA1 or BRCA25,6. Indeed, young age at diagnosis is a criterion to refer patients to genetic counseling irrespective of family history or other tumor biological features4. Identification of a germline pathogenic variant in the BRCA genes plays a crucial role in cancer prevention and treatment7,8. BRCA-related breast cancers have distinct biological features, including a tendency for hormone receptor-negativity in BRCA1 carriers and hormone receptor positivity in BRCA2 carriers9–12.

Several studies have investigated the prognostic role of carrying germline BRCA pathogenic variants13. Compared to women with sporadic breast cancer, current evidence does not support different outcomes in those with BRCA pathogenic variants13. Similarly, no difference in survival outcomes between young breast cancer patients with or without germline BRCA pathogenic variants have been shown, except a trend for a survival advantage in BRCA-mutated patients with triple-negative breast cancer compared with non-carriers6. Nevertheless, besides the known differences in clinicopathological features in breast cancer cases associated with germline BRCA1 or BRCA2 pathogenic variants9–12, there is a lack of evidence so far on whether the type of mutated gene may also lead to potential differences in breast cancer clinical behavior and outcomes. In addition, the prognostic value of hormone receptor status in BRCA-related breast cancers remains largely unknown. We addressed these important issues in a large series of young breast cancer patients harboring germline BRCA pathogenic variants.

Results

Study cohort

Out of 1424 patients registered in the study from 30 centers worldwide, 1236 young BRCA-mutated breast cancer patients were eligible for inclusion in the present analysis (Supplementary Fig. 1).

Among 808 and 428 patients with germline BRCA1 and BRCA2 pathogenic variants, 191 (23.6%) and 356 (83.2%) had hormone receptor-positive tumors, respectively (P < 0.001).

Comparison between patients with germline BRCA1 and BRCA2 pathogenic variants

Compared to patients in the BRCA2 cohort, those in the BRCA1 cohort were younger, more likely to have Israeli origin, had more grade 3 tumors, less lobular histology, nodal involvement, and HER2-positive disease (Table 1). Women in the BRCA1 cohort received chemotherapy more frequently and, among those with hormone receptor-positive disease, fewer patients received adjuvant endocrine therapy (Table 1). Although patients in the BRCA1 cohort underwent breast-conserving surgery more often, no difference was observed in rates of risk-reducing mastectomy or salpingo-oophorectomy between the BRCA1 and BRCA2 cohorts, respectively (Supplementary Table 1).

Table 1.

Patient, tumor and treatment characteristics.

BRCA1 cohort N (%) n = 808 BRCA2 cohort N (%) n = 428 P valuea
Country 0.001
 Europe 611 (75.6) 611 (75.6)
 North America 52 (6.4) 27 (6.3)
 Latin America 34 (4.2) 13 (3.0)
 Israel 111 (13.7) 28 (6.5)
Year at diagnosis 0.33
 2000–2004 167 (20.7) 97 (22.7)
 2005–2008 304 (37.6) 143 (33.4)
 2009–2012 337 (41.7) 188 (43.9)
Age at diagnosis, median (IQR) years 34 (30–37) 36 (33–38) <0.001
Age at diagnosis <0.001
 ≤30 years 206 (25.5) 64 (15.0)
 31–35 years 281 (34.8) 143 (33.4)
 36–40 years 321 (39.7) 221 (51.6)
Histology <0.001
 Ductal carcinoma 645 (79.8) 346 (80.8)
 Lobular carcinoma 10 (1.2) 29 (6.8)
 Others 87 (10.8) 20 (4.7)
 Missing 66 (8.2) 33 (7.7)
Tumor grade <0.001
 G1 10 (1.2) 13 (3.0)
 G2 110 (13.6) 140 (32.7)
 G3 638 (79.0) 251 (58.6)
 Missing 50 (6.2) 24 (5.6)
Tumor size 0.95
 T1 (≤2 cm) 331 (41.0) 176 (41.1)
 T2-T3-T4 (>2 cm) 459 (56.8) 247 (57.7)
 Missing 18 (2.2) 5 (1.2)
Nodal status <0.001
 N0 484 (59.9) 183 (42.8)
 N1-N2-N3 311 (38.5) 240 (56.1)
 Missing 13 (1.6) 5 (1.2)
Hormone receptor status <0.001
 ER and/or PR positive 191 (23.6) 356 (83.2)
 ER and PR negative 617 (76.4) 72 (16.8)
HER2 status <0.001
 HER2 negative 760 (94.1) 380 (88.8)
 HER2 positive 28 (3.5) 40 (9.3)
 Missing 20 (2.5) 8 (1.9)
Breast surgery <0.001
 Breast-conserving surgery 428 (53.0) 158 (36.9)
 Mastectomy 372 (46.0) 264 (61.7)
 Missing 8 (1.0) 6 (1.4)
Use of chemotherapy <0.001
 No 24 (3.0) 33 (7.7)
 Yes 782 (96.8) 395 (92.3)
 Missing 2 (0.2) 0 (0.0)
Type of chemotherapyb 0.63
 Anthracycline- and taxane-based 526 (67.3) 263 (66.6)
 Anthracycline-based 196 (25.1) 110 (27.8)
 Taxane-based 20 (2.6) 11 (2.8)
 Others 19 (2.4) 6 (1.5)
 Missing 21 (2.7) 5 (1.3)
Use of endocrine therapyc <0.001
 No 28 (14.7) 15 (4.2)
 Yes 160 (83.8) 339 (95.2)
 Missing 3 (1.6) 2 (0.6)
Type of endocrine therapyd 0.38
 Tamoxifen alone 71 (44.4) 145 (42.8)
 Tamoxifen + LHRHa 47 (29.4) 116 (34.2)
 LHRHa alone 5 (3.1) 3 (0.9)
 AI ± LHRHa 7 (4.4) 14 (4.1)
 Tamoxifen and AI (±LHRHa) 29 (18.1) 58 (17.1)
 Missing 1 (0.6) 3 (0.9)
Duration of endocrine therapy, median (IQR) months 60 (28.5 to 60) 60 (50 to 60) 0.02
Open in a new tab

IQR interquartile range, G tumor grade, T tumor size, N nodal status, ER estrogen receptor, PR progesterone receptor, LHRHa luteinizing hormone-releasing hormone agonist, AI aromatase inhibitors.

aCalculated after exclusion of missing values.

bCalculated among patients who received chemotherapy.

cCalculated among patients with hormone receptor-positive breast cancer.

dCalculated among patients with hormone receptor-positive breast cancer who received endocrine therapy.

Supplementary Tables 2 and 3 report the comparison in clinicopathological characteristics and risk-reducing surgery between the BRCA1 and BRCA2 cohorts according to hormone receptor status.

Median follow-up was 7.9 years (interquartile range 5.6–10.6 years), with no difference between the BRCA1 and BRCA2 cohorts (P = 0.95). In terms of the first DFS event, second primary malignancies (breast cancer: 17.0% vs. 12.2%, P = 0.009; non-breast cancer: 4.3% vs. 1.9%, P = 0.02) were more frequent in the BRCA1 cohort while distant recurrences were less frequent (10.4% vs. 15.4%, P = 0.02) as compared to the BRCA2 cohort (Table 2). When the pattern of the first DFS event was assessed between the BRCA1 and BRCA2 cohorts according to hormone receptor status, the only difference was a higher rate of second non-breast cancer primary malignancies (5.2% vs. 1.4%, P = 0.005) in the BRCA1 cohort with hormone receptor-positive disease, being mostly ovarian cancer (Supplementary Table 4).

Table 2.

Pattern of invasive disease-free survival events according to a type of BRCA-mutated gene.

BRCA1 cohort N (%) n = 808 BRCA2 cohort N (%) n = 428 P valuea
Follow-up, median (IQR) 7.9 (5.4 to 10.6) 7.9 (6.0 to 10.6) 0.95
No events 492 (60.9) 262 (61.2) 0.76
Loco-regional recurrence 54 (6.7) 36 (8.4) 0.35
Distant recurrence ± loco-regional recurrence 84 (10.4) 66 (15.4) 0.02
Second primary malignancy 35 (4.3) 8 (1.9) 0.02
 Ovarian cancer 18 (2.2) 1 (0.2)
 Other 7 (0.9) 4 (0.9)
 Missing 10 (1.2) 3 (0.7)
Second primary breast cancer 137 (17.0) 52 (12.2) 0.009
Death without any disease-free survival event 6 (0.7) 4 (0.9) 0.79
Open in a new tab

IQR interquartile range.

aP-values for time-dependent events estimated by means of the Log-rank test.

Considering DFS events, a similar pattern of annual HRs was observed between patients in the BRCA1 and BRCA2 cohorts irrespective of hormone receptor status, with a higher risk for those with BRCA1 pathogenic variants (Figs. 1a, 2a, and 3a).

Fig. 1. Comparison between patients with germline BRCA1 and BRCA2 pathogenic variants.

Fig. 1

Open in a new tab

a Epanechnikov Kernel-Smoothed annual hazards of recurrence overall; b Disease-free survival; c Distant recurrence-free interval; d Overall survival.

Fig. 2. Comparison between patients with germline BRCA1 and BRCA2 pathogenic variants and hormone receptor-positive disease.

Fig. 2

Open in a new tab

a Epanechnikov Kernel-Smoothed annual hazards of recurrence overall; b Disease-free survival; c Distant recurrence-free interval; d Overall survival.

Fig. 3. Comparison between patients with germline BRCA1 and BRCA2 pathogenic variants and hormone receptor-negative disease.

Fig. 3

Open in a new tab

a Epanechnikov Kernel-Smoothed annual hazards of recurrence overall; b Disease-free survival; c Distant recurrence-free interval; d Overall survival.

Eight-year DFS was 62.8% and 65.9% in the BRCA1 and BRCA2 cohorts, respectively (adjusted HR = 0.76, 95% CI 0.60–0.96; Fig. 1b). A tendency towards worse DFS in the BRCA1 cohort was observed for both patients with hormone receptor-positive (adjusted HR = 0.77, 95% CI 0.58–1.03; Fig. 2b) and negative (adjusted HR = 0.73, 95% CI 0.48–1.13; Fig. 3b) breast cancer (Pinteraction = 0.85; Supplementary Table 5).

Eight-year DRFI was 88.9% and 83.8% in the BRCA1 and BRCA2 cohorts, respectively (adjusted HR = 0.94, 95% CI 0.64–1.38; Fig. 1c). No significant difference in DRFI was observed for patients with either hormone receptor-positive (adjusted HR = 0.94, 95% CI 0.60–1.48; Fig. 2c) or negative (adjusted HR = 0.92, 95% CI 0.43–1.95; Fig. 3c) breast cancer (Pinteraction = 0.95; Supplementary Table 6).

Eight-year OS was 86.9% and 87.5% in the BRCA1 and BRCA2 cohorts, respectively (adjusted HR = 0.69, 95% CI 0.46–1.04; Fig. 1d). No significant difference in OS was observed for patients with either hormone receptor-positive (adjusted HR = 0.64, 95% CI 0.39–1.05; Fig. 2d) or negative (adjusted HR = 0.80, 95% CI 0.40–1.56; Fig. 3d) breast cancer (Pinteraction = 0.62; Supplementary Table 7).

Comparison between patients with hormone receptor-positive and negative disease

Compared to patients with hormone receptor-negative disease, those with hormone receptor-positive breast cancer were older, had less grade 3 tumors, more often lobular histology, nodal involvement, and HER2-positive disease (Supplementary Table 8). Women with hormone receptor-positive breast cancer were less likely to receive chemotherapy and underwent mastectomy more often than those with hormone receptor-negative disease (Supplementary Table 8). No differences were observed in rates of risk-reducing mastectomy and salpingo-oophorectomy between patients with hormone receptor-positive and negative breast cancer, respectively (Supplementary Table 9).

In terms of first DFS event, patients with hormone receptor-positive breast cancer had a higher incidence of distant (±loco-regional) recurrences (16.1% vs. 9.0%, P < 0.001) and lower incidence of second primary malignancies (breast cancer: 12.1% vs. 17.9%, P = 0.005; non-breast cancer: 2.8% vs. 4.0%, P = 0.18) compared to women with hormone receptor-negative disease (Table 3). A similar pattern of annual HRs was observed between patients with hormone receptor-positive and negative disease until 5 years, beyond which a rapidly increasing trend for those with hormone receptor-positive breast cancer was observed (Fig. 4a).

Table 3.

Pattern of invasive disease-free survival events according to hormone receptor status.

Hormone receptor-positive N (%) n = 547 Hormone receptor-negative N (%) n = 689 P valuea
Follow-up, median (IQR) 7.8 (5.8–10.6) 7.9 (5.5–10.6) 1.00
No events 329 (60.1) 425 (61.7) 0.91
Loco-regional recurrence 45 (8.2) 45 (6.5) 0.28
Distant recurrence +/− loco-regional recurrence 88 (16.1) 62 (9.0) <0.001
Second primary malignancy 15 (2.8) 28 (4.0) 0.18
 Ovarian cancer 7 (1.3) 12 (1.7)
 Other 6 (1.1) 5 (0.7)
 Missing 2 (0.4) 11 (1.6)
Second primary breast cancer 66 (12.1) 123 (17.9) 0.005
Death without any disease-free survival event 4 (0.7) 6 (0.9) 0.75
Open in a new tab

IQR interquartile range.

aP-values for time-dependent events estimated by means of the Log-rank test.

Fig. 4. Comparison between patients with hormone receptor-positive and negative disease.

Fig. 4

Open in a new tab

a Epanechnikov Kernel-Smoothed annual hazards of recurrence overall; b Disease-free survival; c Distant recurrence-free interval; d Overall survival. HR+ hormone receptor-positive; HR− hormone receptor-negative.

As reported in Supplementary Table 10, 8-year DFS was 62.9% and 64.7% in patients with hormone receptor-positive and negative disease, respectively (adjusted HR = 1.06, 95% CI 0.84–1.33; Fig. 4b). Eight-year DRFI was 83.4% and 90.1% in patients with hormone receptor-positive and negative disease, respectively (adjusted HR = 1.39, 95% CI 0.94–2.05; Fig. 4c). Eight-year OS was 87.3% and 87.0% in patients with hormone receptor-positive and negative disease, respectively (adjusted HR = 0.81, 95% CI 0.55–1.20; Fig. 4d).

Considering that the cut-off used for defining hormone receptor positivity was not homogenous in all centers, the analyses comparing between patients with hormone receptor-positive and negative disease were then repeated by including only patients for whom the 1% cut-off for estrogen and/or progesterone receptor expression in their tumor was used to define hormone receptor status. Results were consistent with those reported in the main analyses (Supplementary Tables 11–14 and Supplementary Figs. 2–5).

Discussion

This large unique dataset allowed an in-depth investigation of the impact of the type of mutated gene (BRCA1 vs BRCA2) and hormone receptor status on clinical behavior and outcomes of BRCA-mutated breast cancer in young women. We observed that patients with germline BRCA1 pathogenic variants had worse DFS than those with BRCA2 pathogenic variants, mainly due to higher rates of second primary malignancies (predominantly breast and ovarian cancers) irrespective of hormone receptor status, with no difference in DRFI and OS. Hormone receptor positivity was not associated with favorable prognosis in BRCA-mutated breast cancer, whatever the type of mutated gene, but rather it displayed a tendency for worse DRFI and no difference in DFS and OS compared to hormone receptor-negative disease. These data are highly relevant for counseling young BRCA-mutated breast cancer patients.

In terms of clinicopathological features, as shown in prior studies9–12, the majority of breast cancer cases associated with germline BRCA1 pathogenic variants were hormone receptor-negative tumors (76%) while those arising in BRCA2-mutated patients were hormone receptor-positive (83%). Overall, the majority of tumors were high-grade (60–80%) and HER2-negative (90–95%), both features being particularly relevant in the case of BRCA1 carriers9–12,14. In terms of clinicopathological characteristics in the BRCA1 and BRCA2 cohorts according to hormone receptor status, the features that remained differently distributed were country of origin and tumor grade in patients with hormone receptor-positive disease (more likely Israeli origin and high-grade tumors in the BRCA1 cohort) as well as age and HER2 status in those with hormone receptor-negative tumors (younger age and more likely HER2-negative status in the BRCA1 cohort).

Harboring a germline pathogenic variant in BRCA1 or BRCA2 was not previously shown to have an apparent negative prognostic impact in breast cancer13, neither in young patients6. Compared with non-carriers, a tendency for better survival outcomes in BRCA carriers with triple-negative breast cancer was shown6. In addition, a reverse association of the prognostic value of hormone receptor status was observed between breast cancer patients with or without germline BRCA pathogenic variants6,15, particularly in the case of BRCA2 pathogenic variants16–18. Nevertheless, within the cohort of young BRCA-mutated breast cancer patients, the prognostic implications of carrying a germline BRCA1 or BRCA2 pathogenic variant as well as potential differences according to hormone receptor status remained largely undefined. Two main findings with potential clinical implications were found in our study.

Firstly, irrespective of hormone receptor status, the type of BRCA gene does not appear to have prognostic value, with no observed difference in DRFI and OS between BRCA1- and BRCA2-mutated patients. This is reassuring evidence for counseling young BRCA-mutated breast cancer patients. Nevertheless, BRCA1 carriers showed worse DFS, mostly due to higher rates of second primary malignancies (predominantly breast and ovarian cancers) as compared to BRCA2-mutated patients. This result reflects the different and age-dependent risk of cancer development associated with the two genes: the breast cancer peak of incidence occurs earlier and ovarian cancer risk is higher in BRCA1 carriers as compared to those with BRCA2 pathogenic variants19,20. Young age at cancer diagnosis further increases the risk of second primary breast and ovarian malignancies19,21–23. Therefore, these findings highlight the key role of BRCA genetic testing in this patient population and calls for awareness of the high risk of secondary malignancies and the option of considering risk-reducing surgeries when a pathogenic variant is identified, particularly in BRCA1 carriers24,25. In addition, these results pinpoint the need to consider age-specific risk estimates when offering these procedures during patients’ counseling23.

Secondly, irrespective of the type of BRCA-mutated gene, hormone receptor positivity has no favorable prognostic value in this setting. While no difference in DFS and OS was observed, patients with hormone receptor-positive breast cancer showed a higher risk of distant relapses and a trend for worse DRFI as compared to those with hormone receptor-negative disease. There are several potential explanations for this lack of prognostic advantage in young BRCA-mutated patients with hormone receptor-positive breast cancer. Estrogen signaling was shown to promote tumor initiation and progression in BRCA-deficient cells26,27. Biological differences were reported between hormone receptor-positive breast cancers arising in patients with or without germline BRCA pathogenic variants28,29. When tested with OncotypeDx, a larger proportion of BRCA-mutated patients were found to have high recurrence scores, and low recurrence score was not necessarily associated with low risk of recurrence30–32. Taking into account that our study included only patients ≤40 years at diagnosis, these considerations may be further amplified due to the additional effect of young age on the biology of hormone-receptor-positive breast cancers2,3. Finally, it should be highlighted that BRCA-related tumors are known to have high chemosensitivity11,17,33, particularly in the case of hormone receptor-negative disease34,35. In our study, more than 90% of the patients received chemotherapy. However, ~8% of patients with hormone receptor-positive disease did not receive adjuvant endocrine therapy, with significantly higher numbers of non-recipients among BRCA1 carriers. Although the reasons for lack of endocrine therapy administration were not collected, special attention should be paid in this regard when counseling BRCA-mutated patients with hormone receptor-positive disease. Our findings provide indirect evidence to potentially consider BRCA-mutated patients with hormone receptor-positive disease as a high-risk population36. Therefore, ovarian function suppression37 and extended adjuvant endocrine therapy38 may be considered relevant options in this setting. In light of the increased ovarian cancer risk, risk-reducing salpingo-oophorectomy might be considered as the primary strategy for ovarian function suppression in eligible patients who have completed their family planning.

The findings of this study should be considered in the context of its limitations. This is a retrospective cohort study conducted over a relatively long period of time. Assessment of BRCA and hormone receptor status as well as patient management were conducted according to diagnostic and treatment procedures available at that time in the respective country and center. Median follow-up was shorter than 10 years. Nevertheless, several unique features of this study should also be highlighted. This is a multicenter study, not restricted to a single continent, that included a large sample size despite focusing on a special and rare patient population (i.e., young breast cancer patients with germline BRCA pathogenic variants). The numbers of included patients and registered events made possible the acquisition of reliable results on these important unmet and clinically highly relevant issues.

In conclusion, type of BRCA-mutated gene and hormone receptor status strongly impact the clinical behavior and outcomes of breast cancer in young patients with germline BRCA pathogenic variants. Young patients with germline BRCA1 pathogenic variants had worse DFS than those with germline BRCA2 pathogenic variants mostly due to higher rates of second primary malignancies irrespective of hormone receptor status. On the other hand, unlike breast cancers arising in non-BRCA carriers, hormone receptor status had no prognostic value in young BRCA-mutated patients, and even a tendency of worse DRFI in women with hormone receptor-positive disease was observed. These results provide important information for counseling young BRCA-mutated breast cancer patients regarding treatment, prevention and surveillance strategies.

Methods

Study design and participants

Details of this study were previously reported39. Briefly, this was an international, multicenter, hospital-based, retrospective cohort study that included women diagnosed at age ≤40 years with invasive early breast cancer (stage I–III) between January 2000 and December 2012. All included patients had a known germline BRCA1 or BRCA2 pathogenic variant.

Healthy carriers as well as women with BRCA variants of uncertain significance, other malignancies (including ovarian cancer) without a prior diagnosis of invasive breast cancer, in situ or stage IV de novo breast cancer, or lack of information on follow-up were not eligible for inclusion. For the purpose of the present analysis, patients harboring pathogenic variants in both BRCA1 and BRCA2 as well as those with unknown hormone receptor status were also excluded.

Datasets from countries with more than one participating center were crosschecked to exclude potential duplicated cases.

Procedures

Data on tumor and patient characteristics, treatment, BRCA pathogenic variants, and survival outcomes were collected for all eligible patients.

The type of mutated gene was the criteria used to distinguish between two cohorts of patients: women with BRCA1 (BRCA1 cohort) and those with BRCA2 (BRCA2 cohort) pathogenic variants.

BRCA pathogenic variants and hormone receptor status were assessed locally at each participating center. Hormone receptor positivity was defined by the expression of estrogen and/or progesterone receptors in ≥1% of invasive tumor cells (≥10% in French participating centers) assessed by immunostaining.

The Institut Jules Bordet (Brussels, Belgium) coordinated the study and acted as the central ethics committee. Ethics approval by the Institutional Review Boards of participating centers and patients’ written informed consent were obtained before inclusion whenever requested by local regulations.

The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement was followed for study reporting40.

Outcomes

The current analysis aimed to investigate the impact of the type of mutated gene (BRCA1 vs. BRCA2) and hormone receptor status on clinical behavior and outcomes of young breast cancer patients with germline BRCA pathogenic variants.

Clinicopathological characteristics, pattern, and risk over time of disease-free survival (DFS) events, as well as prognosis (in terms of DFS, distant recurrence-free interval [DRFI], and overall survival [OS]) were compared between the BRCA1 and BRCA2 cohorts. The same analyses comparing the BRCA1 and BRCA2 cohorts were then performed separately in patients with hormone receptor-positive and negative disease.

To specifically assess the effect of hormone receptor status, clinicopathological characteristics, pattern, and risk over time of DFS events, as well as prognosis (in terms of DFS, DRFI, and OS) were compared between patients with hormone receptor-positive and negative disease irrespective of the type of mutated gene.

Statistical analysis

Descriptive analyses were used to assess clinicopathological characteristics as well as the pattern of DFS events.

To assess the risk of developing DFS events over time, the Epanechnikov Kernel-Smoothed annual hazards of recurrence were calculated.

DFS was defined as the time from diagnosis until the first appearance of one of the following invasive events: loco-regional recurrence, distant metastases, new contralateral or ipsilateral breast cancer, second primary malignancy, or death from any cause. DRFI was calculated as the time from diagnosis until the first occurrence of invasive breast cancer recurrence at a distant site. OS was defined as the time from diagnosis until death from any cause.

Observation times of patients that did not experience an event were censored on the date of their last contact. Kaplan–Meier plots were used to present results with a follow-up time of up to 10 years. Cox proportional hazard model was applied to estimate the hazard ratios (HRs) over the whole follow-up period, adjusting for the concomitant effect of selected confounders. Multivariate models for all survival analyses included nodal status, grade, HER2, type of breast surgery, chemotherapy use, age, year of diagnosis, and country.

Homogeneity tests on the HRs were performed in all survival analyses using the likelihood ratio test to assess whether there was evidence of an interaction between the type of gene and hormone receptor status.

All statistical analyses were two-sided; P values < 0.05 were considered as statistically significant. Statistical analyses were performed by MC and MB using Stata 13.1 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP).

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Supplementary information

Online only data supplement (621KB, pdf)
Reporting Summary Checklist (83.5KB, pdf)

Acknowledgements

This study received partial financial support by grants from the Italian Ministry of Health - 5 × 1000 funds 2017 (no grant number), the Italian Association for Cancer Research (AIRC; MFAG 2020 ID 24698), and “Les Amis de l’Institut Bordet” foundation (no grant number). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. M.L. acknowledges the support from the European Society for Medical Oncology (ESMO) for a Translational Research Fellowship at the Institut Jules Bordet in Brussels (Belgium) at the time of study conduction. K.P. acknowledges the support from a predoctoral clinical ‘KOOR’ mandate from the University Hospitals Leuven (Leuven, Belgium). F.P.D. acknowledges the support for a postdoctoral clinical mandate (2017-034) from the not-for-profit organization ‘Foundation Against Cancer’ (Brussels, Belgium). A.H.P. acknowledges the support from Susan G. Komen and Breast Cancer Research Foundation (BCRF). J.H. acknowledges the support from the Carlos III National Health Institute funded by FEDER funds—a way to build Europe (PI16/11363). This research was presented in the Poster Spotlight session at the 2020 San Antonio Breast Cancer Symposium (SABCS), San Antonio, TX, United States of America, on 8–12 December 2020.

Author contributions

Concept and design: M.L. and H.A.A. Jr. Acquisition, analysis, or interpretation of data: M.L., M.C., A.S.H., O.C., P.D.P., E.C., A.G., K.P., C.R.J., A.F., S.P.S, A.T., C.S., F.P., K.P., J.A.P.F., L.D.M., R.P., L.L., M.D.P.E.D., C.V.G., M.V.D., F.C., F.P.D., R.G., L.T, O.C., A.S, A.R.F., A.H.P., A.D.M., C.S., F.A.P., M.B, L.A., M.D.T.K.D.R., J.B., L.D.M. and H.A.A. Jr. Drafting of the manuscript: M.L. Critical revision of the manuscript for important intellectual content: M.C., A.S.H., O.C., P.D.P., E.C., A.G., K.P., C.R.J., A.F., S.P.S, A.T., C.S., F.P., K.P., J.A.P.F., L.D.M., R.P., L.L., M.D.P.E.D., C.V.G., M.V.D., F.C., F.P.D., R.G., L.T, O.C., A.S, A.R.F., A.H.P., A.D.M, C.S., F.A.P., M.B, L.A., M.D.T.K.D.R., J.B., L.D.M. and H.A.A. Jr. Statistical analysis: M.C., M.B. Administrative, technical, or material support: M.L., M.C., A.S.H., O.C., P.D.P., E.C., A.G., K.P., C.R.J., A.F., S.P.S, A.T., C.S., F.P., K.P., J.A.P.F., L.D.M., R.P., L.L., M.D.P.E.D., C.V.G., M.V.D., F.C., F.P.D., R.G., L.T, O.C., A.S, A.R.F., A.H.P., A.D.M, C.S., F.A.P., M.B, L.A., M.D.T.K.D.R., J.B., L.D.M. and H.A.A. Jr. Final approval of the completed version: M.L., M.C., A.S.H., O.C., P.D.P., E.C., A.G., K.P., C.R.J., A.F., S.P.S, A.T., C.S., F.P., K.P., J.A.P.F., L.D.M., R.P., L.L., M.D.P.E.D., C.V.G., M.V.D., F.C., F.P.D., R.G., L.T, O.C., A.S, A.R.F., A.H.P., A.D.M, C.S., F.A.P., M.B, L.A., M.D.T.K.D.R., J.B., L.D.M. and H.A.A. Jr. Accountability for all aspects of the work: M.L., M.C., A.S.H., O.C., P.D.P., E.C., A.G., K.P., C.R.J., A.F., S.P.S, A.T., C.S., F.P., K.P., J.A.P.F., L.D.M., R.P., L.L., M.D.P.E.D., C.V.G., M.V.D., F.C., F.P.D., R.G., L.T, O.C., A.S, A.R.F., A.H.P., A.D.M, C.S., F.A.P., M.B, L.A., M.D.T.K.D.R., J.B., L.D.M. and H.A.A. Jr.

Data availability

The data generated and analysed during this study are described in the following data record: 10.6084/m9.figshare.1350742241. The data are stored in the following four Excel spreadsheets: ‘Patient survival data.xlsx’, ‘Patient baseline, tumor and treatment data.xlsx’, ‘Patient risk-reducing surgery data.xlsx’, ‘Patient eligibility criteria and survival data.xlsx’. These data are not publicly available for the following reason: data contain information that could compromise research participant privacy. However, the data can be made available upon reasonable request to the corresponding author. A list of which data file underlies which figure, table, and supplementary table in the related manuscript is provided in the file ‘Lambertini et al. underlying data lookup.csv’, included as part of the metadata record41. The dataset analysed during this study is described with more details in the following manuscript: 10.1200/JCO.19.0239939.

Competing interests

M.L. acted as a consultant for Roche, AstraZeneca, Lilly and Novartis, and received honoraria from Sandoz, Roche, Novartis, Takeda, Pfizer and Lilly outside the submitted work. O.C. acted as a consultant for AstraZeneca, and received travel grants from Ipsen outside the submitted work. C.R.J. acted as a consultant for Mylan medical, and received honoraria from Theramex and Bayer outside the submitted work. F.P. acted as a consultant for Astrazeneca, Daichii Sankyo, MSD, Novartis, Pierre Fabre, and Roche, received honoraria from Lilly, Novartis, Pfizer, Roche and Takeda, and received research grants from Astrazeneca, EISAI, and Roche outside the submitted work. K.P. acted as a consultant, received speaker honoraria and travel grants from Roche, Novartis, Pfizer, AstraZeneca, Lilly, Pierre Fabre, Egis, Amgen, Angelini and Teva outside the submitted work. J.A.P.F. acted as a consultant for Amgem, Astrazeneca, Clovis, and G.S.K., received honoraria from Roche, Astrazeneca, Novartis, Clovis, and G.S.K. and travel expenses by Roche, Astrazeneca, Pfizer, and G.S.K. outside the submitted work. C.V.G. acted as a consultant for Pfizer, Roche, Novartis, and Lilly, received honoraria from Myriad Genetics, Roche and Novartis, research funding from Roche and AstraZeneca, and travel expenses by Roche, MSD Oncology and Pfizer outside the submitted work. F.C. acted as a consultant for Lilly, BMS and Roche, received speaker honoraria from Merck Serono and BMS, research funding to his institution from AstraZeneca, and travel grants from Roche, Merck Serono, and BMS outside the submitted work. F.P.D. acted as a consultant for Roche, Pfizer, AstraZeneca, Lilly, Amgen, Novartis, Pierre Fabre, and Daiichi Sankyo, and received travel grants from Roche, Pfizer, Teva, and Amgen outside the submitted work. L.T. acted as a consultant for AstraZeneca, Lilly, Novartis, Pfizer, and Roche, received speaker honoraria from AstraZeneca, Merck Serono, Lilly, Novartis, Roche, research funding to his institution from Pfizer and Novartis, and travel grants from Roche, Merck Serono, and AstraZeneca, Novartis and Roche outside the submitted work. A.S. acted as a consultant for Novartis, Roche, Pfizer, and Lilly, received speaker honoraria from Roche, Pfizer, Medison, Lilly, and Novartis, research funding from Novartis, and travel grants from Medison and Roche outside the submitted work. A.R.F. received travel grants from Novartis and Roche outside the submitted work. A.D.M. received honoraria from ThermoFisher outside of the submitted work. J.B. acted as a consultant and received travel grants from Pfizer and Astra Zeneca outside the submitted work. L.D.M. acted as a consultant for Roche, Novartis, MSD, Pfizer, Ipsen, AstraZeneca, Genomic Health, Lilly, Seattle Genetics, Eisai, Pierre Fabre, and Daiichi Sankyo, received speaker honoraria from Roche, Novartis, Lilly and MSD, and travel grants from Roche, Pfizer and Celgene outside the submitted work. H.A.A. Jr acted as a consultant for Roche, received honoraria from Novartis outside the submitted work, and reported employment at Innate Pharma at the end of this study; this employment is not related in any sort to the subject of the current study. All the other authors declare no competing interests.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Lucia Del Mastro, Hatem A. Azim Jr.

Supplementary information

The online version contains supplementary material available at 10.1038/s41523-021-00224-w.

References

  • 1.Fidler MM, et al. Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study. Lancet Oncol. 2017;18:1579–1589. doi: 10.1016/S1470-2045(17)30677-0. [DOI] [PubMed] [Google Scholar]
  • 2.Azim HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16:427. doi: 10.1186/s13058-014-0427-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Partridge AH, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J. Clin. Oncol. 2016;34:3308–3314. doi: 10.1200/JCO.2015.65.8013. [DOI] [PubMed] [Google Scholar]
  • 4.Paluch-Shimon, S. et al. ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Ann. Oncol.31, 674–696 (2020). [DOI] [PubMed]
  • 5.Rosenberg SM, et al. BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol. 2016;2:730–736. doi: 10.1001/jamaoncol.2015.5941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Copson ER, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19:169–180. doi: 10.1016/S1470-2045(17)30891-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Paluch-Shimon S, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann. Oncol. 2016;27:v103–v110. doi: 10.1093/annonc/mdw327. [DOI] [PubMed] [Google Scholar]
  • 8.Tung NM, et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J. Clin. Oncol. 2020;38:2080–2106. doi: 10.1200/JCO.20.00299. [DOI] [PubMed] [Google Scholar]
  • 9.Eerola H, et al. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2005;7:R93–R100. doi: 10.1186/bcr953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Atchley DP, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol. 2008;26:4282–4288. doi: 10.1200/JCO.2008.16.6231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Goodwin PJ, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J. Clin. Oncol. 2012;30:19–26. doi: 10.1200/JCO.2010.33.0068. [DOI] [PubMed] [Google Scholar]
  • 12.Spurdle AB, et al. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res. 2014;16:3419. doi: 10.1186/s13058-014-0474-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.van den Broek AJ, Schmidt MK, van’t Veer LJ, Tollenaar RAEM, van Leeuwen FE. Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what’s the evidence? A systematic review with meta-analysis. PLoS ONE. 2015;10:e0120189. doi: 10.1371/journal.pone.0120189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Evans DG, et al. Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. Breast Cancer Res. Treat. 2016;155:597–601. doi: 10.1007/s10549-016-3697-z. [DOI] [PubMed] [Google Scholar]
  • 15.Vocka, M. et al. Estrogen receptor status oppositely modifies breast cancer prognosis in BRCA1/BRCA2 mutation carriers versus non-carriers. Cancers11, 738 (2019). [DOI] [PMC free article] [PubMed]
  • 16.Jonasson JG, et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br. J. Cancer. 2016;115:776–783. doi: 10.1038/bjc.2016.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Schmidt, M. K. et al. Breast cancer survival of BRCA1/BRCA2 mutation carriers in a hospital-based cohort of young women. J. Natl. Cancer Inst. 109 (2017). [DOI] [PubMed]
  • 18.Metcalfe K, et al. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br. J. Cancer. 2019;120:398–403. doi: 10.1038/s41416-019-0376-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kuchenbaecker KB, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–2416. doi: 10.1001/jama.2017.7112. [DOI] [PubMed] [Google Scholar]
  • 20.Mavaddat N, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J. Natl. Cancer Inst. 2013;105:812–822. doi: 10.1093/jnci/djt095. [DOI] [PubMed] [Google Scholar]
  • 21.Graeser MK, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J. Clin. Oncol. 2009;27:5887–5892. doi: 10.1200/JCO.2008.19.9430. [DOI] [PubMed] [Google Scholar]
  • 22.Berkowitz Z, Rim SH, Peipins LA. Characteristics and survival associated with ovarian cancer diagnosed as first cancer and ovarian cancer diagnosed subsequent to a previous cancer. Cancer Epidemiol. 2011;35:112–119. doi: 10.1016/j.canep.2010.07.001. [DOI] [PubMed] [Google Scholar]
  • 23.van den Broek AJ, et al. Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers. J. Clin. Oncol. 2016;34:409–418. doi: 10.1200/JCO.2015.62.3942. [DOI] [PubMed] [Google Scholar]
  • 24.Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N. Engl. J. Med. 2016;374:454–468. doi: 10.1056/NEJMra1503523. [DOI] [PubMed] [Google Scholar]
  • 25.Dullens, B. et al. Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines. J. Oncol. 9873954 (2020). [DOI] [PMC free article] [PubMed]
  • 26.Baek HJ, et al. Inhibition of Estrogen Signaling Reduces the Incidence of BRCA1-associated Mammary Tumor Formation. Int. J. Biol. Sci. 2018;14:1755–1768. doi: 10.7150/ijbs.28142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Wang C, et al. Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression. Breast Cancer Res. 2018;20:74. doi: 10.1186/s13058-018-0996-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Tung N, et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res. 2010;12:R12. doi: 10.1186/bcr2478. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Lips EH, et al. BRCA1-mutated estrogen receptor-positive breast cancer shows BRCAness, suggesting sensitivity to drugs targeting homologous recombination deficiency. Clin. Cancer Res. 2017;23:1236–1241. doi: 10.1158/1078-0432.CCR-16-0198. [DOI] [PubMed] [Google Scholar]
  • 30.Lewin R, et al. Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations. Breast Cancer Res. Treat. 2016;157:511–516. doi: 10.1007/s10549-016-3836-6. [DOI] [PubMed] [Google Scholar]
  • 31.Shah PD, et al. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation status. Cancer. 2016;122:1178–1184. doi: 10.1002/cncr.29903. [DOI] [PubMed] [Google Scholar]
  • 32.Halpern N, et al. Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer. Int. J. Cancer. 2017;140:2145–2149. doi: 10.1002/ijc.30616. [DOI] [PubMed] [Google Scholar]
  • 33.Huzarski T, et al. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J. Clin. Oncol. 2013;31:3191–3196. doi: 10.1200/JCO.2012.45.3571. [DOI] [PubMed] [Google Scholar]
  • 34.Jiang T, et al. Predictors of chemosensitivity in triple negative breast cancer: an integrated genomic analysis. PLoS Med. 2016;13:e1002193. doi: 10.1371/journal.pmed.1002193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Tung N, et al. TBCRC 031: Randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial) J. Clin. Oncol. 2020;38:1539–1548. doi: 10.1200/JCO.19.03292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Lambertini M, Blondeaux E, Perrone F, Del, Mastro L. Improving adjuvant endocrine treatment tailoring in premenopausal women with hormone receptor-positive breast cancer. J. Clin. Oncol. 2020;38:1258–1267. doi: 10.1200/JCO.19.02242. [DOI] [PubMed] [Google Scholar]
  • 37.Burstein HJ, et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J. Clin. Oncol. 2016;34:1689–1701. doi: 10.1200/JCO.2015.65.9573. [DOI] [PubMed] [Google Scholar]
  • 38.Burstein HJ, et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J. Clin. Oncol. 2019;37:423–438. doi: 10.1200/JCO.18.01160. [DOI] [PubMed] [Google Scholar]
  • 39.Lambertini M, et al. Pregnancy after breast cancer in patients with germline BRCA mutations. J. Clin. Oncol. 2020;38:3012–3023. doi: 10.1200/JCO.19.02399. [DOI] [PubMed] [Google Scholar]
  • 40.von Elm E, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–1457. doi: 10.1016/S0140-6736(07)61602-X. [DOI] [PubMed] [Google Scholar]
  • 41.Lambertini, M. et al. Metadata record for the manuscript: clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. figshare 10.6084/m9.figshare.13507422 (2020). [DOI] [PMC free article] [PubMed]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Online only data supplement (621KB, pdf)
Reporting Summary Checklist (83.5KB, pdf)

Data Availability Statement

The data generated and analysed during this study are described in the following data record: 10.6084/m9.figshare.1350742241. The data are stored in the following four Excel spreadsheets: ‘Patient survival data.xlsx’, ‘Patient baseline, tumor and treatment data.xlsx’, ‘Patient risk-reducing surgery data.xlsx’, ‘Patient eligibility criteria and survival data.xlsx’. These data are not publicly available for the following reason: data contain information that could compromise research participant privacy. However, the data can be made available upon reasonable request to the corresponding author. A list of which data file underlies which figure, table, and supplementary table in the related manuscript is provided in the file ‘Lambertini et al. underlying data lookup.csv’, included as part of the metadata record41. The dataset analysed during this study is described with more details in the following manuscript: 10.1200/JCO.19.0239939.

Articles from NPJ Breast Cancer are provided here courtesy of Nature Publishing Group

RESOURCES